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Abstract In Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB) -synuclein (S) pathology is seen that
displays a predictable topographic distribution. There are two
staging/categorization systems, i.e. Braak’s and McKeith’s,
currently in use for the assessment of S pathology. The
aim of these diagnostic strategies in pathology is, in addi-
tion to assess the stage/severity of pathology, to assess the
probabilities of the related clinical symptomatology i.e.
dementia and extrapyramidal symptoms (EPS). Herein, we
assessed the applicability of these two staging/categoriza-
tion systems and the frequency of dementia and EPS in a
cohort of 226 S-positive-subjects. These subject were
selected from a large autopsy sample (n = 1,720), irrespec-
tive of the clinical presentation, based on the detection of
S-immunoreactivity (IR) in one of the most vulnerable
nuclei; in the dorsal motor nucleus of vagus, substantia
nigra and basal forebrain. The frequency of S-IR lesions
in this large cohort was 14% (248 out of 1,720). If applica-
ble, each of the 226 subjects with all required material
available was assigned a neuropathological stage/category
of PD/DLB and Wnally the neuropathological data was ana-
lyzed in relation to dementia and EPS. 83% of subjects
showed a distribution pattern of S-IR that was compatible
with the current staging/categorization systems. Around
55% of subjects with widespread S pathology (Braak’s PD
stages 5–6) lacked clinical signs of dementia or EPS. Simi-
larly, in respect to those subjects that fulWlled the McKeith
criteria for diVuse neocortical category and displaying only
mild concomitant Alzheimer’s disease-related pathology,
only 48% were demented and 54% displayed EPS. It is
noteworthy that some subjects (17%) deviated from the
suggested caudo-rostral propagation suggesting alternative
routes of progression, perhaps due to concomitant diseases
and genetic predisposition. In conclusion, our results do
indeed conWrm that current staging/categorization systems
can readily be applied to most of the subjects with S
pathology. However, Wnding that around half of the sub-
jects with abundant S pathology remain neurologically
intact is intriguing and raises the question whether we do
assess the actual disease process.
Keywords Dementia · Extrapyramidal symptoms · 
Lewy body dementia · Parkinson disease · -Synuclein
Introduction
There are two staging/categorization systems commonly in
use for the assessment of the progressive regional distribu-
tion of the pathology seen in Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB). Both of these staging/
categorization systems are based on the assessment of mis-
folded -synuclein (S) protein within selectively vulnerable
neuronal populations which is considered to be either
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directly responsible or at least intimately linked to the neu-
ronal dysfunction seen in PD and DLB. In this respect, S-
immunoreactive (IR)-inclusions in the brainstem have been
claimed to be responsible for the extrapyramidal symptoms
(EPS), whereas dementia has been attributed to the limbic
and neocortical spread of these lesions. Thus, PD and DLB
are thought to form a clinico-pathologic continuum wherein
the clinical manifestation of EPS and/or dementia depends
on the anatomical distribution and the load of S pathology
[4, 17, 19, 25, 28, 30].
In 2003, Braak and colleagues reported that the S
pathology begins in clearly deWned induction sites and
advances, not in a random, but in a predictable sequence
with increasing severity throughout the brain [4, 11]. Based
on the analysis of the regional distribution of S-IR inclu-
sions in a cohort including both neurologically unimpaired
subjects and patients with PD, a staging system was
devised whereby S pathology was divided into six succes-
sive stages. In the central nervous system, the proposed
sequence begins in the dorsal motor nucleus of vagus
(dmV), and then proceeds with an upward progression via
locus coeruleus (LC) (stage 2) to the substantia nigra (SN)
(stage 3), and then to the basal foreberain (BFB) and tran-
sentorhinal region (stage 4) until it Wnally reaches the neo-
cortex (stages 5–6).
Already in 1996, the consortium on DLB international
workshop proposed their consensus guidelines for the clini-
cal and pathologic diagnosis of DLB [27] that later, in 2005
were somewhat revised [28]. These consensus criteria of
DLB subdivide subjects into three diVerent neuropathologi-
cal categories; brainstem predominant, limbic/transitional
and diVuse neocortical depending on the anatomical distri-
bution of the S-IR structures [28]. These criteria also
include the semiquantitative grading of lesion density,
although the pattern of regional involvement has been
assumed to be more important than the actual count of
inclusions. It is noteworthy that in the revised recommen-
dations by McKeith et al from 2005 [28], it is emphasized
that the concomitant pathologies should be taken into
account when assessing the causative relationships between
pathologies and symptoms. Thus, the most common pathol-
ogy seen in aged demented individuals, i.e. Alzheimer’s
disease (AD)-related pathology, should be evaluated while
assessing the likelihood of causation, i.e. that the S pathol-
ogy is associated with a DLB clinical syndrome.
Herein, we assess the applicability of these two current
staging/categorization systems of synucleinopathies in a
large autopsy material collected, not on the basis of clinical
presentation, but by S immunoreactivity in some of the
most vulnerable nuclei; dmV, SN and BFB. Thus, the
selection of material was entirely based on the presence of
S pathology irrespective of clinical phenotype. All sub-
jects, if applicable, were assigned a stage following in
detail Braak staging recommendations and a McKeith
neuropathological category following in detail recommen-
dations by the consortium on DLB international workshop
[4, 28]. The frequency of dementia and EPS was assessed
in each stage and the likelihood that dementia was due to
AD-related pathology or S pathology was also examined.
Materials and methods
Selection of subjects and the clinical assessment
The Xowchart delineates the logistics of this study (Fig. 1).
A total of 1,720 elderly individuals (age at death >40 years)
that had undergone an autopsy together with an examina-
tion of the brain during the years 1996–2005 in the Kuopio
University Hospital were included in this study. From this
large autopsy sample, we selected 248 (14%) subjects that
displayed S-IR structures in the SN and/or BFB nuclei:
nucleus basalis of Meynert (nbM) and amygdaloid complex
(AC). Screening of dmV was also carried out in 1996–2000
and revealed that in 24 subjects out of 904 (3%) S-IR-
structures were restricted to the lower brain stem nuclei
(dmV and/or LC) [33]. Five subjects were excluded from
the analysis because they had received a pathological diag-
nosis of MSA. Seventeen subjects were excluded due to
lack of clinical information or inadequate amount of brain
material required for the classiWcation as recommended by
Mc Keith and Braak [4, 28], and thus ultimately, this study
examined 226 subjects.
The diagnosis of dementia was based on the DSM-III
criteria and the criteria of the National Institute of Neu-
rological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) [29]. The diagnosis of PD followed
the criteria established by the United Kingdom Parkinson’s
Disease Society Brain Bank whereby PD was considered
present if the patient had at least two of the four cardinal
symptoms (resting tremor, rigidity, hypokinesia and pos-
tural instability) and exhibited a positive response to levo-
dopa [9]. The initial screening for both dementia and EPS
had taken place in a primary health care centre. With
respects to dementia, all patients scoring 26 or less in mini-
mental State Examination (MMSE) had been referred to a
neurologist for further evaluation and all patients scoring
>26 in MMSE but displaying signs of memory impairment
had been referred to a CERAD test. Consequently, many
subjects had been examined by a neurologist and all had at
least visited a general physician (within a maximum of
1 year before death). It is noteworthy that many of the sub-
jects included in this study had been under continuous clin-
ical follow-up due to some chronic disease. Admittedly,
some subjects may have developed subtle extrapyramidalActa Neuropathol (2008) 115:399–407 401
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signs or mild cognitive impairment between the last clinical
examination and death, but it is most unlikely that the pres-
ence of moderate or full-blown parkinsonian syndrome/
dementia would have been overlooked.
Neuropathological assessment
According to the dissection protocol used in the Kuopio
University Hospital, the brains were weighed, evaluated for
grossly detectable lesions and vessel abnormalities, per-
fused with and immersed in 10% buVered formalin for at
least one week and cut in coronal slices of 1 cm thickness.
Brain specimens were embedded in paraYn and cut into
7 m-thick sections. Immohistochemical (IHC) methodol-
ogy was used to visualize the expression of S and hyper-
phosphorylated  (HP). The sections were deparaVinized
and rehydrated according to a routine procedure. For S
IHC, the sections were autoclaved (120°C) in citrate buVer
for 10 min and pretreated with 80% formic acid at room
temperature for 5 min. Monoclonal antibodies to human
S1–140 (Novocastra, Newcastle upon Tyne, UK) at a dilu-
tion of 1:1,000 and to human HP at a dilution of 1:500
(Innogenetics, Ghent, Belgium) were applied. For detec-
tion, Histostain SP kit (Zymed, San Francisco, CA) was
used with Romulin AEC chromogen (Biocare Medical,
Walnut Creek, CA). The expression of S was assessed in
Fig. 1 The Xowchart delineat-
ing the logistics of this study. 
a The S-immunoreactive inclu-
sions were screened in substantia 
nigra, amygdaloid complex and 
dorsal motor nucleus of vagus. 
b Schematic presentation of both 
Braak staging and McKeith 
categorization [4, 28] and 
c schematic presentation of 
assessment of likelihood that 
S-immunoreactive inclusion 
are associated with dementia 
with Lewy bodies [28]
Braak stage McKeith category
1 2 3 4 5 6 I II III
1. medullad orsal motor
nucleus of vagus
+/++ +/++ +/++/+++ ++/+++ ++/+++ +++ 1-3 1-3 1-3
locus coeruleus 0 + +//++/+++ ++/+++ ++/+++ ++/+++ 1-3 1-3 1-3
Raphe nucleus 0 + +/++ +/++/+++ ++/+++ ++/+++
3. midbrain substantia nigra 0 0 +/++/+++ ++/+++ ++/+++ +++ 1-3 1-3 1-3
nucleus basalisof 
Meynert
0 0 +/++/+++ +/++/+++ ++/+++ +++ 0-2 2-3 2-3
amygdaloid
complex
00 I R IR IR IR 0-2 2-3 3-4
(trans)entorhinal
cortex
00 0 + / + + + + + + / + + + 0 - 1 1 - 3 2 - 4
CA2 region 0 0 + +/++ +/++/+++ ++/+++
temporo-occipital
gyrus
0 0 0 +/++ ++ ++/+++
6. insularc o r t e x 0 0 0 0 + + +
7. cingulate gyrus0 0 0 0 + + + 0 - 1 1 - 3 2 - 4
8. temporal gyrus0 0 0 0 + + + 0 0 - 2 2 - 3
9. frontalc o r t e x 0 0 0 0 0 + 0 0 - 1 1 - 3
10. parietal cortex 0 0 0 0 0 + 0 0 0-2
5. hippocampus
4. basal forebrain
2. pons
Section Anatomical region
a) Screening of αS immunoreactivity in the SN, nbM and AC and dmV in 1720 subjects (age at death 
±40 years) that underwent an autopsy during the years 1996-2005 in the  Kuopio University hospital
226 αS-positives ubjects
b) To assign the Braak stage and the McKeith neuropathological category of Parkinson's disease related 
pathology, αSi m m unohistochemistry was carried out on all 10 sections listed below. Both assignments are 
based on semiquantitative assessment and regional distribution of αS-immunoreactive structures.  
Intermediate High High Diffuse neocortical
Low Intermediate High Limbic transitional
Low Low Low Brainstem predominant
Braaks t age V-VI Braaks t age III-IV Braaks t age 0-II
Alzheimer type pathology Category of
Lewy body type pathology
c)  In order to assess the likelihood that the αS-immunoreactive lesions are associated with a DLB  
clinical syndrome, Alzheimer's Disease related neurofibrillary pathology was assessed using AT8  
IHC and staged as recommended by Braak
SN
AC
nbM DMV402 Acta Neuropathol (2008) 115:399–407
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10 brain regions: (1) medulla with dmV; (2) pons with LC
and raphe nucleus (RN); (3) midbrain with SN; (4) BFB
including nbM, AC, and transentorhinal cortex; (5) poster-
ior hippocampus at the level of geniculate nucleus including
the CA2 region of the hippocampus and temporo-occipital
gyrus; (6) insular cortex; (7) anterior cingulate gyrus; (8)
superior temporal gyrus (Broadman area 22); (9) frontal
cortex (Broadman area and (10) parietal cortex (Broadman
areas 39, 40). The selection of regions was based on the
currently used staging systems [4, 28] (See Fig. 1). HP IHC
was carried out on sections from hippocampus, temporal and
occipital cortices and the regional distribution of AD-related
neuroWbrillary pathology was subdivided into 6 stages (I-VI)
as has been described previously [6].
The number of S-IR inclusions was counted within the
microscopic Weld at £200 magniWcation (diameter of 1 mm)
and assessed semiquantitatively in all brain areas examined.
The total thickness of the cortical grey matter and AC were
assessed according to the established pathological guide-
lines [28] and rated as follows: 1 = mild (sparse inclusions
at £100); 2 = moderate (>1 inclusion in low power Weld
at £200 magniWcation); 3 = severe (¸4 inclusions in low
power  Weld at £200 magniWcation); 4 = very severe
(numerous inclusions). In the nbM and all subcortical
regions, S-IR inclusions were counted unilaterally within
entire nuclei and assessed following an arbitrary grading
system: in nbM and SN, + =mild (<25 inclusions); ++ =
moderate (25–50 inclusions); +++ = severe (>50 inclu-
sions), in LC and dmV, + = mild (1–2 inclusions);
++ = moderate (2–10 inclusion), +++ = severe (>10 inclu-
sions). Several inclusions within one neuron were counted
as a single inclusion. The S-IR structures were designated
as being present (+) or not (0) in raphe nucleus and CA2
region of the hippocampus. If no S-IR inclusions were
identiWed in the sections of medulla, pons, midbrain or BFB,
the result was veriWed in at least 3–4 consecutive sections
i.e. the subsequent 5th, 10th, 15th and 20th sections were
stained. This was done in order to increase the likelihood of
capturing incipient neurons with S-IR inclusions.
Results
Assessment of clinical data
The 226 S-positive subjects examined included 114 (50%)
patients with a clinical diagnosis of a neurodegenerative
disorder, 15 (7%) patients with other neurological disorders
and 97 (43%) individuals in whom the clinical information
indicated that they had no neurological impairment. The
mean age at death was 77 § 0.6 years, ranging from 44 to
98 years and the gender was rather evenly distributed (108
females/118 males).
Frequency of S-immunoreactivity in the most vulnerable 
anatomical regions
The most frequently aVected regions in the 226 S-positive
subjects were dmV (197/223) and SN (197/225) where the
S-IR was seen in 88% of the analyzed subjects. The LC was
aVected in 81% (181/223) of subjects, making this area the
second most vulnerable nuclei. The large neurons in the nbM
were S-immunopositive in 78% of cases (171/219), whereas
the involvement of AC, particularly the cortico-medial
nuclear group, was seen in 73% (162/223) of subjects.
Staging of Parkinson disease-related S pathology 
according to Braak and the frequency of dementia 
and extrapyramidal symptoms
Out of the 226 S-positive subjects, 187 (83%) displayed a
distribution pattern of S-IR that was compatible with the
current staging systems of PD/DLB-related synucleinop-
athies [4,  28]. Braak stage 1–2 was applicable for 22
subjects, 3–4 for 38 subjects and 5–6 for 127 subjects
(Table 1). When all subjects with severe AD-related neuro-
Wbrillary pathology, i.e. Braak’s AD stage V-VI, were
excluded, 168 cases of the 187 subjects remained. Notably,
only 25–30% of the subjects with PD-related Braak stage 5
and 50% of subjects with PD-related Braak stage 6 were
demented and/or had EPS. It is noteworthy that when only
demented subjects were included in the analysis (53 out of
168), 91% (48/53) were assigned to PD-related Braak
stages5–6. Similarly, when only subjects with EPS were
included in the analysis (52 out of 168), 94% (49/52) were
in the PD-related Braak stages 5–6.
Categorization of the distribution of S pathology 
following the recommendations by the consortium on 
DLB international workshop, i.e. McKeith’s categorization, 
and the frequency of dementia and extrapyramidal 
symptoms
Sixty-six subjects fulWlled Mc Keith’s criteria for the brain-
stem predominant form, 30 for the limbic (transitional) and
91 for the diVuse neocortical form of DLB (Table 2).
Fifty-seven percent of subjects with the diVuse neocortical
form of DLB were demented and 47% displayed EPS
(Table 2). When AD-related pathology was taken into account
as suggested by McKeith and colleagues [28] (Table 3), the
percentage of demented in the high likelihood category var-
ied from 24 to 60%. Irrespective of the S pathology, in
Braak’s AD stage V-VI, all subjects were demented. Nota-
bly, when only demented subjects were included in the
analysis and the subject with severe AD-related pathology
(Braak’s AD stage V-VI) were excluded, 85% (45/53) were
assigned to a high likelihood category of DLB.Acta Neuropathol (2008) 115:399–407 403
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Atypical cases i.e. cases that could not be classiWed 
as recommended
Thirty-nine cases were not classiWable as recommended
and thus were assigned as being atypical i.e. neither Braak
staging nor McKeith categorization systems could be
applied. The deviating topographical distribution of S-IR
inclusions of these subjects is shown in Table 4. In four
subjects, the BFB nuclei (AC predominant) were severely
aVected (cases 1–4) together with some cortical inclusions,
whereas the brainstem had been preserved. Five subjects
displayed isolated minor involvement of SN without any
S-IR inclusions in the lower brainstem nuclei (cases 5–9).
In six subjects (cases 10–15) minor involvement of both SN
and BFB nuclei was detected (cases 10–15). In addition to
these two areas, three cases exhibited severe S pathology
in AC (cases 16–18, AC predominant). In seven subjects,
some inclusions were seen in the BFB, SN and LC, but not
Parkinson's disease related pathology staged as recommended by Braak Distribution of αS-positive  
structures 12 3 4 5 6
dorsal motor nucleus of vagus n=10
locus coeruleus
raphe nucleus
n=11
substantia nigra
nucleus basalis of Meynert
CA2 region
n=16
amygdaloid complex
(trans)entorhinal  cortex
temporo-occipital gyrus
n=22
insular cortex
cingulate gyrus
temporal gyrus
n=25
frontal cortex
parietal cortex
n=84
number with dementia (%)   0 (0%)   1 (9%)   0 (0%)   4 (18%)   6 (25%)   42 (50%)
number with  EPS (%)   0 (0%)   1 (9%)   2 (13%)   0 (0%)   7 (28%)   42 (50%)
number of all cases, i.e. 
Braak’s AD stages V-VI  also 
included
10 12 16 22 28 99
Table 1 Applicability of Braak 
staging and the incidence of 
dementia and extrapyramidal 
signs (EPS) in each stage
Parkinson's disease related pathology categorized as recommended by McKeith and colleagues Distribution of  αS-positive
structures Brainstem predominant Limbic transitionalD i f f use neocortical
dorsal motor nucleus of vagus
locus coeruleus
raphe nucleus
substantia nigra
nucleus basalis of Meynert
amygdaloid complex
(trans)entorhinal cortex
cingulate gyrus
n=66
temporal gyrus
frontal cortex
n=30
parietal cortex
n=91
number with dementia (%)                   8 (12%)                    11 (37%)                      52 (57%)
number with EPS (%)                   5 (8%)                    10 (33%)                      43 (47%)
Table 2 Applicability of neuro-
pathological categorization as 
recommended by the consortium 
on DLB international workshop, 
i.e. McKeiths categorization and 
the incidence of dementia and 
extrapyramidal signs (EPS) 
in each category
Table 3 Assessment of likeli-
hood that the pathological 
Wndings are associated with 
a DLB clinical syndrome
Category of Lewy 
body type pathology
Alzheimer type pathology
Braak stage 0-II Braak stage III-IV Braak stage V-VI
Brainstem predominant 
n =6 6
Low 
n = 58 
5 demented (9%) 
5 with EPS (9%)
Low 
n =7  
2 demented (29%) 
0 with EPS (0%)
Low 
n =1  
1 demented (100%) 
0 with EPS (0%)
Limbic transitional 
n =3 0
High 
n = 25 
6 demented (24%) 
9 with EPS (36%)
Intermediate 
n =1  
1 demented (100%) 
0 with EPS (0%)
Low 
n =4  
4 demented (100%) 
1 with EPS (25%)
DiVuse neocortical 
n =9 1
High 
n = 63 
30 demented (48%) 
34 with EPS (54%)
High 
n =1 5  
9 demented (60%) 
4 with EPS (29%)
Intermediate 
n =1 3  
13 demented (100%) 
5 with EPS (36%)404 Acta Neuropathol (2008) 115:399–407
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Table 4 Topographic distribution of S immunoreactive lesions in the 39 atypical cases, i.e. not classiWable following current recommendations
EPS extrapyramidal signs, Dem clinical signs of dementia, AD stage the stage of Alzheimer’s disease related neuroWbrillary pathology stages as
recommended by Braak from 0 to VI., dmV dorsal motor nucleus of vagus, RN raphe nucleus, LC locus coeruleus, SN substantia nigra, nbM nucleus
basalis of Meynert, AC amygdaloid complex, TrEntCx transentorhinal cortex, CA2 CA2 region of the Cornu Ammonis of the hippocampus, Temp-
Occ temporo-occipital gyrus, Ins Cx insular cortex, CG cingulate gyrus, TCx temporal cortex, FCx frontal cortex, PCx parietal cortex; na not avail-
able. The S-immunoreactive inclusions were examined in the total thickness of the cortical grey matter and AC and rated as follows: 1 mild (sparse
inclusions in £100), 2 moderate (>1 inclusion in £200 magniWcation), 3 severe (¸4 inclusions in £200 magniWcation), 4 very severe (numerous
inclusions), in the nbM and subcortical regions, S- immunoreactive inclusions were counted unilaterally within entire nuclei and assessed follow-
ing an arbitrary grading system: in nbM and SN, + mild (<25 inclusions), ++ moderate (25–50 inclusions), +++ severe (>50 inclusions), and
in LC and dmV, + mild (1–2 inclusions), ++ moderate (2–10 inclusion), +++ severe (>10 inclusions). In Raphe nucleus and CA2 region of the
hippocampus, S-immunoreactive structures (inclusion and/or neurites) were marked to be present (+) or not (0)
ID Age Sex EPS Dem AD stage Topographical distribution of S-immunoreactive structures
dmV RN LC SN nbM AC TrEnt Cx CA2 Temp-Occ Ins Cx CG TCx FCx PCx
1 79 F No Yes 4 0 0 0 0 0 4 1 0 0 0 0 0 0 0
2 62 F No Yes 6 0 0 0 0 0 4 2 0 1 0 0 0 0 0
3 74 F No Yes 2 0 0 0 0 + 4 2 0 2 0 1 1 0 0
4 7 9FY e s Y e s 6 0 000 + 30 0 0 1 11 0 0
5 86 F No No 4 0 0 0 + 0 0 0 0 0 0 0 0 0 0
6 44 M No No 0 0 0 0 + 0 0 0 0 0 0 0 0 0 0
7 68 M No No 1 0 0 0 + 0 0 0 0 0 0 0 0 0 0
8 83 M No No 2 0 0 0 + 0 0 0 0 0 0 0 1 0 0
9 83 M No No 1 0 + 0 + 0 0 0 0 0 0 0 0 0 0
10 75 F No No 0 0 0 0 + + 0 0 0 0 0 0 0 0 0
11 76 M No No 1 0 0 0 + + 0 0 0 0 0 0 2 0 0
12 70 M No No 0 0 0 0 + + 0 0 0 0 0 0 0 0 0
13 77 F No No 2 0 0 0 + + 2 1 0 0 0 0 0 0 0
14 73 M Yes Yes 2 0 0 0 ++ + 0 0 0 0 0 0 1 0 0
15 71 F No Yes 6 0 0 0 +++ + 0 0 0 1 1 1 1 0 0
16 79 F No Yes 5 0 0 0 + 0 3 3 0 0 1 0 0 0 0
17 87 F No Yes 2 0 0 0 + + 4 na na 0 0 0 0 0 0
18 74 F No Yes 6 0 0 0 + na 4 na + 1 0 0 0 0 0
19 62 M Yes Yes 0 0 0 + + 0 0 0 0 0 0 0 0 0 0
20 79 M No Yes 0 0 0 + + + 0 0 0 0 0 0 0 0 0
21 84 F No Yes 2 0 0 + + ++ 0 0 0 0 0 0 0 0 0
22 85 F No No 0 0 0 + + + 1 1 na na 0 0 0 0 0
23 82 F No Yes 3 0 0 + + ++ na 2 0 0 1 0 0 0 0
24 58 M No No 0 0 0 + +++ ++ 0 0 0 0 0 0 0 0 0
25 84 M No No 3 0 0 + +++ + 3 2 0 1 0 2 0 0 0
26 76 M No No 1 + 0 0 + 0 0 0 0 0 0 0 0 0 0
27 87 F No No 1 + 0 0 + + 0 0 0 0 na 0 0 0 0
28 78 M No No 1 + 0 0 + + 2 2 0 0 0 0 0 0 0
29 84 F No Yes 5 + 0 0 + 0 1 na + 1 0 0 0 0 0
30 75 F Yes Yes 5 ++ 0 0 + 0 1 0 0 0 0 0 0 0 0
31 60 F No No 0 +++ 0 0 + 0 0 0 0 0 0 0 0 0 0
32 80 M No Yes 6 + 0 0 ++ 0 0 0 0 0 0 1 0 0 0
33 69 M No No 1 ++ + 0 ++ ++ 1 1 0 0 0 1 0 0 0
34 80 M Yes Yes 5 ++ 0 0 ++ + 3 2 + 1 1 1 0 0 0
35 86 F No Yes 6 + + 0 + 0 4 4 + 3 0 0 1 0 0
36 64 F No Yes 6 + 0 0 + na 4 na + na 0 0 1 0 0
37 74 F No Yes 6 + 0 0 + + 4 4 0 na 0 1 2 0 0
38 78 M No Yes 5 + 0 0 + + 3 3 + 1 2 1 1 0 0
39 89 M No No 2 + 0 0 + + 2 2 0 0 0 1 1 1 0Acta Neuropathol (2008) 115:399–407 405
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in the dmV (cases 19–25). In the Wnal 14 subjects (cases
26–39), inclusions were seen in the dmV and SN, but not in
the LC, together with variable aVection of BFB and other
cortical regions. In only minority of these cases EPS symp-
toms were seen (13%), whereas dementia was more com-
mon (54%). In 14 cases dementia was due to AD-related
neuroWbrillary pathology (Braak stage V-VI), in six cases
numerous multifocal microscopic infarcts and concomitant
severe white matter rarefaction was considered as the causa-
tive agent regarding dementia and in one cases neuropatho-
logical lesions consistent with frontotemporal dementia with
ubiquitin only lesions were seen.
Discussion
Most of our (83%) S-positive cases could be assigned to
one of the six PD stages as described by Braak and also into
the brainstem, limbic or diVuse neocortical neuropathologi-
cal category as recommended by McKeith and colleagues
[4, 28]. Braak and colleagues depicted the topographical
distribution of S-IR structures by assessing 110 S-posi-
tive subjects (69 incidental and 41 symptomatic PD
patients) [4]. The initial intent of Braak and colleagues was
not to correlate the designated neuropathological stages
with clinical symptoms, however this was later contem-
plated [5]. Stages 1 and 2, i.e. stages where S pathology
is conWned to the dmV and/or LC, are considered to be
presymptomatic, whereas EPS appear and the cognitive
decline increases with each stage. In stage 3, when SN is
aVected, EPS appear and subsequently in stage 4 when
amygdaloid complex, transentorhinal region and temporo-
occipital gyrus become involved, moderate cognitive
impairment is observed (MMSE scores 21–24) and Wnally
in stage 5 and 6 when the neocortex succumbs to the
pathology, severe cognitive impairment is evident (MMSE
scores 11–20 and 0–10, respectively) [5]. Our results also
suggest that the risk of EPS increases with disease progres-
sion though not to the same extent as earlier reported. In
our study, we found one subject with EPS already in stage
2, whereas none of our cases in stage 4 displayed EPS, and
more importantly no EPS had been reported in 55% of sub-
jects who exhibited widespread pathology (Braak stages 5–
6), i.e. this being compared with the 14% previously
reported by Braak and colleagues [4].
The initial decline in cognition was postulated to occur
already during stages 3 and 4 i.e. around the same time
when the initial manifestation of somatosensor dysfunction
start to appear. When assessing 88 subjects, Braak and col-
leagues reported, that 36% of their subjects in stage 3, 67%
in stage 4, 94% in stage 5 and 100% in stage 6 were
demented [5]. This is clearly in odds with our results where
the percentage of demented increased from none to 50%
between stages 3–6. It is noteworthy that when only
demented subjects were included, 91% were assigned to
PD-related Braak stages 5–6 and when only subjects with
EPS were included, 94% were in the PD-related Braak
stages 5–6. Thus the key diVerence between our study when
compared to most other clinico-pathological correlation
studies that have reported good correlation between risk of
disease and progression of pathology is the study design
[5]. Consequently, when we only included subjects with
clinical signs in our analysis the correlation between stage/
severity of S pathology and EPS/dementia was excellent
in line with previous reports.
PD and DLB are distinguished as separate clinical enti-
ties and in 1996 the consortium of the DLB international
workshop subdivided the neuropathological features of
DLB into three categories: brainstem predominant, limbic
and diVuse neocortical type [27]. The foundation of these
three categories is also based on the progressive propaga-
tion of S pathology along a caudo-striatal axis. Similarly
to the Braak staging [4], when applying this categorization
it is presumed that 100% of subjects with widespread S
pathology, i.e. in the diVuse neocortical stage all will be
demented and display EPS. When we followed the classiW-
cation strategy proposed by McKeith and colleagues [28],
our results also diVered from those expected, i.e. only a
subset of our subjects who were classiWed to be in the
diVuse neocortical category displayed dementia and/or EPS
(57 and 47%, respectively). In line with the above, when
only demented subjects were included in the analysis the
correlation between S pathology and dementia was close
to excellent (85%).
The clinical relevance of cortical S pathology in rela-
tion to dementia is a matter of intense debate. Some authors
have emphasized their key causative role [1, 18, 21, 26],
whereas others have reported that there may be abundant
cortical pathology in non-demented PD patients [8] as well
as in neurologically unimpaired subjects [10, 24, 32]. It is
noteworthy that the current study diVers signiWcantly from
most other studies since it is based on neuropathologiacal
Wndings rather than on clinical presentation. Our results
emphasize that abundant pathology may be detected in
many subjects without notable signs of dementia (MMSE
>26) (43%), if it is sought. This has one unexpected conse-
quence, i.e. a detailed regional assessment of S pathology
cannot reliably predict the clinical status observed premor-
tem [33].
There has been much discussion concerning the signiW-
cance and inXuence of concomitant AD-related pathology,
particularly as this is quite frequently seen in aged subjects.
Therefore, the revised consensus criteria have recom-
mended taking AD-related pathology into account while
assessing subjects with suspected DLB [28]. It was pre-
sumed that this would increase the diagnostic speciWcity406 Acta Neuropathol (2008) 115:399–407
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since it was believed that the pathological substrate behind
DLB was indeed S pathology. When we assessed our
unique material, we found, that within the neuropathologi-
cal high likelihood categories of DLB, i.e. those cases
where limbic/diVuse neocortical S pathology is combined
with mild/moderate AD-related changes, 56% of subjects
remained cognitively intact. However, when we examined
only demented subjects without severe AD-related pathol-
ogy (Braak’s AD stage V-VI), 85% were assigned to a high
likelihood category of DLB. This shows that when S
pathology is examined in clinically demented subjects, the
correlation received between particular pathologic change
and dementia is good. It is noteworthy that with respect of
AD-related neuroWbrillary pathology, all cases in the neo-
cortical stage (Braak stage V-VI) were indeed demented.
One important issue with respect to the pathogenesis of
synucleinopathies is not only to understand the molecular
mechanisms behind the intracytoplasmic aggregation of S,
but also to appreciate where this process Wrst appears and
how it may progress through the brain. Thus, many recent
studies have attempted to localize the most vulnerable neu-
ronal populations. In this study, dmV and SN were found to
be equally susceptible nuclei, but even earlier aVected
structures have been reported to appear in the spinal cord,
dmV, olfactory bulb and AC [2, 4, 11, 16, 22, 35]. Thus,
mapping out the “trigger site” for S pathology appears to
depend on the screening process i.e. if one screens medulla
alone, those cases where lesions are restricted to other areas
(e.g. SN) are not found and vice versa.
At variance to the studies of Del Tredici and Braak [4,
11] we identiWed a number of subjects where dmV and/or
LC were not aVected but S-IR inclusions were found in
the SN, BFB and or other cortical regions, and thus, the
distribution of S pathology did not strictly follow the
caudo-rostral propagation pattern described by Braak and
colleagues [4]. Thus, the proposed ascending pathway is
not the only possible route and our results indicate that
pathology can emerge simultaneously in subcortical and
cortical regions. Jellinger has also reported subjects with
multiple S-IR inclusions but with preservation of medul-
lary nuclei [20]. Furthermore, in some subjects we found
the AC to be devoid of pathology although S-IR structures
were detected elsewhere in the neocortex. This refutes the
proposal that in order to have neocortical involvement then
the subcortical lesions have to expand through the basal
forebrain nuclei. In addition, according to Braak and
colleagues [4], the S pathology in previously involved
regions should become exacerbated with disease progres-
sion. It is diYcult to evaluate this proposal when one takes
into account the increasing neuronal loss. If these two path-
ological hallmarks are linked in a causative chain, the load
of S-IR structures should show an inverted u-shape distri-
bution over time where the number of inclusions would
increases with the progression of the disease until the
neurons start to die [12].
We observed some cases with severe S pathology in
AC and in that situation this structure was either only
involved region or was aVected together with BFB and SN.
All these subjects were demented and exhibited coexistent
severe AD-related pathology (Braak AD stage V-VI [6]).
In one case, the dementia was considered to be vascular in
origin. This is in line with the results of Uchikado and col-
leagues who have reported the AC predominant form to be
common Wnding among patients with AD [35].
In conclusion, our results conWrm that the current stag-
ing/categorization systems can readily be applied to most of
the subjects when assessing regional distribution of S-
pathology. It is noteworthy, however, that outliers do exist
and in these cases the presumed distribution may have been
modiWed by other coexisting pathologies or genetic factors
[23, 35]. It is intriguing that around every second subject
displaying abundant pathology did remain neurologically
intact. It is noteworthy that these results were seen when a
rather unselected sample of cases was investigated. It has
been suggested that the key lesions begin to develop a con-
siderable time prior to the appearance of clinical symptoms
[13], but based on our results there do seem to be some sub-
jects who can tolerate substantial amounts of pathology. As
only 50% of subjects with widespread S pathology were
demented (MMSE < 26) and displayed EPS, the clinical
relevance of S-IR inclusions as such still remains to be
resolved. Hitherto, the aggregation of S has been thought
to lead to neuronal death but recent evidence has suggested
that the formation of large inclusions may actually repre-
sent a protective process [3,  14,  34]. Many biophysical
studies have suggested that it is a protoWbrillar form of S
rather than the “mature” Wbrils that are responsible for the
cell death [7, 15, 36], and moreover, the Wbrillar form that
is typically observed at autopsy may actually be a sign of a
well functioning neuroprotection [31, 34]. Thus, when we
are assessing regional distribution of S pathology, the
question arises if we are really evaluating a stage of degen-
eration or conversely monitoring the level of functional
neuroprotection.
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